Cooley Reps SteadyMed In $216M Sale To United Therapeutic
Biopharmaceutical firm United Therapeutics Corp. on Monday said that it will pay $216 million to take over specialty pharmaceutical company SteadyMed Ltd., with Cooley LLP guiding the seller....To view the full article, register now.
Already a subscriber? Click here to view full article